Charles River Laboratories International, Inc.

CRL • Medical - Diagnostics & Research

$288.50

▼ -4.85 (-1.65%)

Precio actual

ResultadosÚltimo reporte: 27 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$13.99B

Crecimiento

5.6%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Flujo de caja libre positivo · 10.46Flujo de caja libre consistente · 5/5Rentabilidad débil

Datos financieros hasta: 27 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 27 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:29 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$288.50

Change-1.65%

Shares Out48.49M

Market Cap$13.99B

Enterprise Value$16.82B

52W Range144.26 - 267.99

Beta1.40

P/E-58.66

P/S3.50

P/B4.93

P/FCF37.74

EV/Sales4.21

Price$288.50

Change-1.65%

Shares Out48.49M

Market Cap$13.99B

Enterprise Value$16.82B

52W Range144.26 - 267.99

Beta1.40

P/E-58.66

P/S3.50

P/B4.93

P/FCF37.74

EV/Sales4.21

EV/EBITDA22.92

EV/FCF45.40

Earnings Yield-1.70%

FCF Yield2.65%

Dividend Yield0.00%

Gross Margin30.52%

Oper. Margin12.65%

Profit Margin-3.59%

Debt/Eq0.97

Current Ratio1.29

Quick Ratio1.02

Revenue 5Y5.56%

FCF 5Y5.48%

Target$267.60

Target Upside-7.24%

Target Median$273.00

Target Range219.00 - 300.00

Volume1.31M

Avg Volume880.34K

EPS Surprise0.10

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

39/100

Fortaleza financiera

Deuda, caja, estabilidad

65/100

Potencial de crecimiento

Ingresos y expansión

44/100

Atractivo del precio

Barata o cara hoy

76/100

Por qué este puntaje▼

Flujo de caja libre positivo · 10.46Flujo de caja libre consistente · 5/5Rentabilidad débil

Analyst view

Analyst sentiment and price target

CRL

Analyst sentiment

Based on 37 analyst votes · 2026-09-05

86/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$219.00

Promedio

$255.78

Mediana

$250.00

Alto

$300.00

Resumen de la compañía

IPO: 6/23/2000

Industria: Medical - Diagnostics & Research

P/B i: 4.93

Deuda / Patrimonio i: 0.97

Margen operativo: 12.65%

Margen neto: -3.59%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 0.97

Ratio corriente: 1.29

Ratio rápido: 1.02

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Parisotto Shannon M

Transacción: 08/05/2026

VENTA

Cambio

-5,046

Precio

$263.00

Presentación

08/06/2026

Tipo

VENTA

FOSTER JAMES C

Transacción: 06/29/2026

VENTA

Cambio

-75,000

Precio

$225.00

Presentación

07/01/2026

Tipo

VENTA

Parisotto Shannon M

Transacción: 06/05/2026

COMPRA

Cambio

+1,529

Precio

Not reported

Presentación

06/08/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Parisotto Shannon M	VENTA	-5,046	$263.00	08/05/2026	08/06/2026
FOSTER JAMES C	VENTA	-75,000	$225.00	06/29/2026	07/01/2026
Parisotto Shannon M	COMPRA	+1,529	Not reported	06/05/2026	06/08/2026
Girshick Birgit	VENTA	-3,386	Not reported	06/05/2026	06/08/2026
FOSTER JAMES C	VENTA	-10,000	Not reported	06/05/2026	06/08/2026
Barg Steven	COMPRA	+422	$174.79	06/02/2026	06/03/2026
Parisotto Shannon M	VENTA	-170	$180.71	05/31/2026	06/02/2026
Creamer Victoria L	VENTA	-194	$180.71	05/31/2026	06/02/2026
Girshick Birgit	VENTA	-378	$180.71	05/31/2026	06/02/2026
Knell Michael Gunnar	VENTA	-48	$180.71	05/31/2026	06/02/2026
LaPlume Joseph W	VENTA	-235	$180.71	05/31/2026	06/02/2026
Mintz Mark	VENTA	-64	$180.71	05/31/2026	06/02/2026
Parisotto Shannon M	VENTA	-551	$180.71	05/30/2026	06/02/2026
Creamer Victoria L	VENTA	-616	$180.71	05/30/2026	06/02/2026
FOSTER JAMES C	VENTA	-1,596	$180.71	05/30/2026	06/02/2026
Girshick Birgit	VENTA	-1,204	$180.71	05/30/2026	06/02/2026
Knell Michael Gunnar	VENTA	-152	$180.71	05/30/2026	06/02/2026
LaPlume Joseph W	VENTA	-744	$180.71	05/30/2026	06/02/2026
Mintz Mark	VENTA	-305	$180.71	05/30/2026	06/02/2026
Parisotto Shannon M	COMPRA	+4,361	$180.71	05/29/2026	06/02/2026

Sobre la compañía

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Fuente - Link

Competidores

AVTR BAX BIO CAI DVA PEN QGEN RNA RVTY

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Zacks Investment Research

Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC)

Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares

Defense World

Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.

According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.

The Motley Fool

Great Lakes Advisors LLC Makes New $459,000 Investment in Charles River Laboratories International, Inc. $CRL

Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company's stock, valued at approximately $459,000. A

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	1.96	2.06	0.1
2026-02-18	2.33	2.39	0.06
2025-11-05	2.32	2.43	0.11
2025-08-06	2.5	3.12	0.62
2025-05-07	2.06	2.34	0.28
2025-02-19	2.5	2.66	0.16
2024-11-06	2.42	2.59	0.17
2024-08-07	2.39	2.8	0.41
2024-05-09	2.06	2.27	0.21
2024-02-14	2.39	2.46	0.07
2023-11-08	2.35	2.72	0.37
2023-08-09	2.63	2.69	0.06